Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning.

Manak MS, Varsanik JS, Hogan BJ, Whitfield MJ, Su WR, Joshi N, Steinke N, Min A, Berger D, Saphirstein RJ, Dixit G, Meyyappan T, Chu HM, Knopf KB, Albala DM, Sant GR, Chander AC.

Nat Biomed Eng. 2018 Oct;2(10):761-772. doi: 10.1038/s41551-018-0285-z. Epub 2018 Sep 17.

2.

Management Options for Nocturia at a Large Urology Group Practice.

Albala DM, Sussman DO.

Rev Urol. 2018;20(3):115-118. doi: 10.3909/riu0820. No abstract available.

3.

Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?

Sant GR, Knopf KB, Albala DM.

NPJ Precis Oncol. 2017 Jun 15;1(1):21. doi: 10.1038/s41698-017-0025-y. eCollection 2017. Review.

4.

Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.

Albala DM.

Rev Urol. 2017;19(3):200-202. doi: 10.3909/riu193PracticeProfile. No abstract available.

5.

A discussion on the AUA castrateresistant prostate cancer guidelines.

Albala DM, Penson DF.

Rev Urol. 2017;19(2):125-128. No abstract available.

6.

Rapid and Short-term Extracellular Matrix-mediated In Vitro Culturing of Tumor and Nontumor Human Primary Prostate Cells From Fresh Radical Prostatectomy Tissue.

Chander AC, Manak MS, Varsanik JS, Hogan BJ, Mouraviev V, Zappala SM, Sant GR, Albala DM.

Urology. 2017 Jul;105:91-100. doi: 10.1016/j.urology.2017.03.029. Epub 2017 Mar 29.

PMID:
28365358
7.

Advanced prostate cancer in large group practices.

Albala DM, Kirsh GM, Shore ND.

Rev Urol. 2016;18(4):226-230. doi: 10.3909/riu0737. No abstract available.

8.

Prostate Cancer Academy 2016: Presentation summaries.

Crawford ED, Albala DM, Wysocki JS, Lepor H, Ross AE, Finkelstein SE, Keane T, Freedland S, Harris R, Shore ND, Ryan CJ.

Rev Urol. 2016;18(4):205-213. doi: 10.3909/riuPCA2016. No abstract available.

9.

Robotic-assisted surgery and treatment of urolithiasis.

Siddiqui KM, Albala DM.

Int J Surg. 2016 Dec;36(Pt D):673-675. doi: 10.1016/j.ijsu.2016.11.031. Epub 2016 Nov 14. Review.

10.

Associated Medical Professionals, Syracuse, NY.

Albala DM, Mariados NF, Pieczonka CM.

Rev Urol. 2016;18(1):35-7. No abstract available.

11.

Prevalence and risk factors of contralateral extraprostatic extension in men undergoing radical prostatectomy for unilateral disease at biopsy: A global multi-institutional experience.

Bienz M, Hueber PA, Trudeau V, Alenizi AM, Valdivieso R, Alom M, Balbay MD, Canda AE, Mouraviev V, Albala DM, El-Hakim A, Trinh QD, Latour M, Saad F, Zorn KC.

Can Urol Assoc J. 2015 Jul-Aug;9(7-8):E434-8. doi: 10.5489/cuaj.2786.

12.

Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat.

Albala DM, Riebman JB, Kocharian R, Ilie B, Albanese J, Shen J, Ovington L, Batiller J.

Rev Urol. 2015;17(1):25-30.

13.

A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy.

Bianco FJ, Albala DM, Belkoff LH, Miles BJ, Peabody JO, He W, Bradt JS, Haas GP, Ahlering TE.

J Urol. 2015 Apr;193(4):1305-10. doi: 10.1016/j.juro.2014.09.106. Epub 2014 Oct 2.

PMID:
25281778
14.

Current status of pelvic lymph node dissection in prostate cancer.

Aleksic I, Luthringer T, Mouraviev V, Albala DM.

J Robot Surg. 2014 Mar;8(1):1-6. doi: 10.1007/s11701-013-0439-7. Epub 2013 Dec 11.

PMID:
27637231
15.

Per aspera ad astra (Through hardship to the stars).

Albala DM, Mouraviev V, Samavedi S.

J Robot Surg. 2013 Sep;7(3):213-4. doi: 10.1007/s11701-013-0426-z. No abstract available.

PMID:
27000916
16.

The transurethral suprapubic endo-cystostomy (T-SPeC): a novel suprapubic catheter insertion device.

Karsh LI, Egerdie RB, Albala DM, Flynn BJ.

J Endourol. 2013 Jul;27(7):880-5. doi: 10.1089/end.2013.0053. Epub 2013 May 28.

17.

Detailed analysis of patients with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institutional study.

Kim IY, Modi PK, Sadimin E, Ha YS, Kim JH, Skarecky D, Cha DY, Wambi CO, Ou YC, Yuh B, Park S, Llukani E, Albala DM, Wilson T, Ahlering T, Badani K, Ahn H, Lee DI, May M, Kim WJ, Lee DH.

J Urol. 2013 Aug;190(2):527-34. doi: 10.1016/j.juro.2013.02.073. Epub 2013 Feb 26.

PMID:
23485503
18.

Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy.

Lughezzani G, Zorn KC, Budäus L, Sun M, Lee DI, Shalhav AL, Zagaya GP, Shikanov SA, Gofrit ON, Thong AE, Albala DM, Sun L, Cronin A, Vickers AJ, Karakiewicz PI.

Eur Urol. 2012 Oct;62(4):590-6. doi: 10.1016/j.eururo.2012.04.022. Epub 2012 May 2.

19.

Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy.

Schroeck FR, Krupski TL, Stewart SB, Bañez LL, Gerber L, Albala DM, Moul JW.

J Urol. 2012 Mar;187(3):894-8. doi: 10.1016/j.juro.2011.10.135. Epub 2012 Jan 15.

PMID:
22245326
20.

Apical surgical margins status in robot-assisted laparoscopic radical prostatectomy does not depend on disease characteristics.

Tsivian M, Zilberman DE, Ferrandino MN, Madden JF, Mouraviev V, Albala DM.

J Endourol. 2012 Apr;26(4):361-5. doi: 10.1089/end.2011.0336. Epub 2012 Jan 10.

PMID:
22192106
21.

Developing a successful robotics program.

Luthringer T, Aleksic I, Caire A, Albala DM.

Curr Opin Urol. 2012 Jan;22(1):40-6. doi: 10.1097/MOU.0b013e32834d5455. Review.

PMID:
22037321
22.

A randomized trial of aprotinin-free fibrin sealant versus absorbable hemostat.

Fischer CP, Wood CG, Shen J, Batiller J, Hart JC, Patel B, Albala DM.

Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):572-7. doi: 10.1177/1076029611404212. Epub 2011 Aug 25.

PMID:
21873356
23.

Optimization of treatment strategy used during shockwave lithotripsy to maximize stone fragmentation efficiency.

Yong DZ, Lipkin ME, Simmons WN, Sankin G, Albala DM, Zhong P, Preminger GM.

J Endourol. 2011 Sep;25(9):1507-11. doi: 10.1089/end.2010.0732. Epub 2011 Aug 11.

PMID:
21834658
24.

Pathologic evaluation of hemostatic agents in percutaneous nephrolithotomy tracts in a porcine model.

Lipkin ME, Mancini JG, Simmons WN, Raymundo ME, Yong DZ, Wang AJ, Ferrandino MN, Albala DM, Preminger GM.

J Endourol. 2011 Aug;25(8):1353-7. doi: 10.1089/end.2011.0041. Epub 2011 Jul 8.

PMID:
21740197
25.

Positive surgical margins after robotic assisted radical prostatectomy: a multi-institutional study.

Patel VR, Coelho RF, Rocco B, Orvieto M, Sivaraman A, Palmer KJ, Kameh D, Santoro L, Coughlin GD, Liss M, Jeong W, Malcolm J, Stern JM, Sharma S, Zorn KC, Shikanov S, Shalhav AL, Zagaja GP, Ahlering TE, Rha KH, Albala DM, Fabrizio MD, Lee DI, Chauhan S.

J Urol. 2011 Aug;186(2):511-6. doi: 10.1016/j.juro.2011.03.112. Epub 2011 Jun 15.

PMID:
21680001
26.

Does body mass index have an impact on the rate and location of positive surgical margins following robot assisted radical prostatectomy?

Zilberman DE, Tsivian M, Yong D, Ferrandino MN, Albala DM.

Urol Oncol. 2012 Nov-Dec;30(6):790-3. doi: 10.1016/j.urolonc.2010.10.004. Epub 2011 Apr 1.

PMID:
21458309
27.

Surgical steps that elongate operative time in robot-assisted radical prostatectomy among the obese population.

Zilberman DE, Tsivian M, Yong D, Albala DM.

J Endourol. 2011 May;25(5):793-6. doi: 10.1089/end.2010.0428. Epub 2011 Mar 7.

PMID:
21381945
28.

Clinical predictors of renal mass pathological features.

Tsivian M, Mouraviev V, Albala DM, Caso JR, Robertson CN, Madden JF, Polascik TJ.

BJU Int. 2011 Mar;107(5):735-740. doi: 10.1111/j.1464-410X.2010.09629.x. Epub 2010 Nov 5.

29.

Predictors of prolonged operative time during robot-assisted laparoscopic radical prostatectomy.

Yong DZ, Tsivian M, Zilberman DE, Ferrandino MN, Mouraviev V, Albala DM.

BJU Int. 2011 Jan;107(2):280-2. doi: 10.1111/j.1464-410X.2010.09511.x. Epub 2010 Aug 12.

30.

Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.

D'Amico AV, Chen MH, Sun L, Lee WR, Mouraviev V, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW.

BJU Int. 2010 Dec;106(11):1618-22. doi: 10.1111/j.1464-410X.2010.09447.x.

31.

Predicting non-organ-confined prostate cancer in men diagnosed after 2000.

Caire AA, Sun L, Lack BD, Lum K, Tang P, Stackhouse DA, Robertson CN, Mouraviev V, Polascik TJ, Albala DM, Moul JW.

Prostate Cancer Prostatic Dis. 2010 Sep;13(3):248-51. doi: 10.1038/pcan.2010.15. Epub 2010 Jun 1.

PMID:
20514082
32.

Endopyelotomy in the age of laparoscopic and robotic-assisted pyeloplasty.

Yong D, Albala DM.

Curr Urol Rep. 2010 Mar;11(2):74-9. doi: 10.1007/s11934-010-0090-z. Review.

PMID:
20425093
33.
34.

Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center.

Tsivian M, Chen VH, Kim CY, Zilberman DE, Mouraviev V, Nelson RC, Albala DM, Polascik TJ.

Eur Urol. 2010 Jul;58(1):142-7. doi: 10.1016/j.eururo.2010.03.035. Epub 2010 Mar 30.

PMID:
20363550
35.

Predicting occult multifocality of renal cell carcinoma.

Tsivian M, Moreira DM, Caso JR, Mouraviev V, Madden JF, Bratslavsky G, Robertson CN, Albala DM, Polascik TJ.

Eur Urol. 2010 Jul;58(1):118-26. doi: 10.1016/j.eururo.2010.03.011. Epub 2010 Mar 17.

PMID:
20346577
36.

Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.

Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW.

Cancer. 2010 Apr 15;116(8):1887-92. doi: 10.1002/cncr.25013.

37.

Dual-energy computed tomography with advanced postimage acquisition data processing: improved determination of urinary stone composition.

Ferrandino MN, Pierre SA, Simmons WN, Paulson EK, Albala DM, Preminger GM.

J Endourol. 2010 Mar;24(3):347-54. doi: 10.1089/end.2009.0193.

PMID:
20105031
38.

Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.

Uhlman MA, Sun L, Stackhouse DA, Polascik TJ, Mouraviev V, Robertson CN, Albala DM, Moul JW.

J Urol. 2010 Mar;183(3):997-1001. doi: 10.1016/j.juro.2009.11.046. Epub 2010 Jan 20.

PMID:
20089281
39.

Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW.

J Urol. 2010 Mar;183(3):946-50. doi: 10.1016/j.juro.2009.11.021. Epub 2010 Jan 18.

PMID:
20083275
40.

Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW.

Urology. 2010 Nov;76(5):1058-62. doi: 10.1016/j.urology.2009.09.049. Epub 2009 Dec 29.

PMID:
20035982
41.

A comprehensive review of topical hemostatic agents: efficacy and recommendations for use.

Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH.

Ann Surg. 2010 Feb;251(2):217-28. doi: 10.1097/SLA.0b013e3181c3bcca. Review.

PMID:
20010084
42.

The impact of societal changes on patterns of urolithiasis.

Zilberman DE, Yong D, Albala DM.

Curr Opin Urol. 2010 Mar;20(2):148-53. doi: 10.1097/MOU.0b013e3283353b6d. Review.

PMID:
19940772
43.

Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?

Uhlman MA, Sun L, Stackhouse DA, Caire AA, Polascik TJ, Robertson CN, Madden J, Vollmer R, Albala DM, Moul JW.

Urology. 2010 Feb;75(2):460-6. doi: 10.1016/j.urology.2009.06.059. Epub 2009 Oct 12.

44.

Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.

Caire AA, Sun L, Robertson CN, Polascik TJ, Maloney KE, George DJ, Price MM, Stackhouse DA, Lack BD, Albala DM, Moul JW.

Urology. 2010 May;75(5):1122-7. doi: 10.1016/j.urology.2009.06.091. Epub 2009 Oct 7.

PMID:
19815259
45.

Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.

Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW.

J Urol. 2009 Nov;182(5):2242-8. doi: 10.1016/j.juro.2009.07.034. Epub 2009 Sep 16.

PMID:
19758616
46.

A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.

D'Alonzo RC, Gan TJ, Moul JW, Albala DM, Polascik TJ, Robertson CN, Sun L, Dahm P, Habib AS.

J Clin Anesth. 2009 Aug;21(5):322-8. doi: 10.1016/j.jclinane.2008.09.005. Epub 2009 Aug 22.

PMID:
19700296
47.

Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.

Xu DD, Sun SD, Wang F, Sun L, Stackhouse D, Polascik T, Albala DM, Moul JW, Caire A, Robertson CN.

Urology. 2009 Sep;74(3):654-8. doi: 10.1016/j.urology.2008.12.063. Epub 2009 Jul 22.

PMID:
19628263
48.

Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: recommendations of the society of urologic robotic surgeons.

Zorn KC, Gautam G, Shalhav AL, Clayman RV, Ahlering TE, Albala DM, Lee DI, Sundaram CP, Matin SF, Castle EP, Winfield HN, Gettman MT, Lee BR, Thomas R, Patel VR, Leveillee RJ, Wong C, Badlani GH, Rha KH, Eggener SE, Wiklund P, Mottrie A, Atug F, Kural AR, Joseph JV; Members of the Society of Urologic Robotic Surgeons.

J Urol. 2009 Sep;182(3):1126-32. doi: 10.1016/j.juro.2009.05.042. Epub 2009 Jul 21. Review.

PMID:
19625032
49.

Do nonspecific deep corticomedullary sutures performed during partial nephrectomy adequately control major vascular and collecting system injury?

L'esperance JO, Marguet CG, Walters RC, Sung JC, Auge BK, Stroup SP, L'esperance AH, Albala DM.

BJU Int. 2010 Feb;105(3):411-5. doi: 10.1111/j.1464-410X.2009.08710.x. Epub 2009 Jun 22.

50.

Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?

Caire AA, Sun L, Ode O, Stackhouse DA, Maloney K, Donatucci C, Mouraviev V, Polascik TJ, Robertson CN, Albala DM, Moul JW.

Urology. 2009 Sep;74(3):643-7. doi: 10.1016/j.urology.2009.02.049. Epub 2009 Jun 7.

PMID:
19501891

Supplemental Content

Loading ...
Support Center